FDA spotlights PML cases in new addition to Gilenya label

Novartis ($NVS) has faced safety questions on its multiple sclerosis pill Gilenya before, prompted by reports of progressive multifocal leukoencephalopathy in its users. Now, the FDA is updating the drug's official label to highlight two more PML reports in patients not previously treated with immunosuppressant drugs. Report

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.